Edwards Lifesciences Corporation Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before December 13, 2024 to Discuss Your Rights - EW

NEW YORK, NY / ACCESSWIRE / November 1, 2024 / If you suffered a loss on your Edwards Lifesciences Corporation (NYSE:EW) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:

https://zlk.com/pslra-1/edwards-lifesciences-lawsuit-submission-form?prid=110291&wire=1

or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212) 363-7500 to speak to our team of experienced shareholder advocates.

THE LAWSUIT:A class action securities lawsuit was filed against Edwards Lifesciences Corporation that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between February 6, 2024 and July 24, 2024.

CASE DETAILS:According to the complaint, defendants provided investors with material information concerning Edwards ' expected revenue for the fiscal year 2024, particularly as it related to the growth of the Company 's core product, Transcatheter Aortic Valve Replacement ("TAVR"). Defendants ' statements included, among other things, strong commitment to the TAVR platform, confidence in the Company 's ability to capitalize on a subset of untreated patients through scaling of its various patient activation activities, and continued claims of significant demand in allegedly lower-penetrated markets.

On July 24, 2024, Edwards unveiled below-expectation financial results for the second quarter of fiscal 2024 and, in particular, slashed its revenue guidance for the TAVR platform for the full fiscal year 2024. The Company attributed the TAVR setback on the "continued growth and expansion of structural heart therapies … [which] put pressure on hospital workflows." Investors understood this to mean that developments in new procedures, including defendant 's own Transcatheter Mitral and Tricuspid Therapies ("TMTT"), put significant strain on hospital structural heart teams such that they were underutilizing TAVR, despite the Company 's continued claim of a significantly undertreated patient population. Moreover, the Company announced three acquisitions during the second quarter designed to embolden their treatments alternative to TAVR, suggesting further that the company was aware of the potential for the TAVR platform 's decelerated growth.

Investors and analysts reacted immediately to Edwards ' revelations. The price of Edwards ' common stock declined dramatically. From a closing market price of $86.95 per share on July 24, 2024, Edwards ' stock price fell to $59.70 per share on July 25, 2024, a decline of about 31.34% in the span of just a single day.

WHAT 'S NEXT?If you suffered a loss in Edwards stock during the relevant time frame - even if you still hold your shares - go to https://zlk.com/pslra-1/edwards-lifesciences-lawsuit-submission-form?prid=110291&wire=1 to learn about your rights to seek a recovery. There is no cost or obligation to participate.

WHY LEVI & KORSINSKY:Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services ' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
https://zlk.com/

SOURCE:Levi & Korsinsky, LLP

View the original press release on accesswire.com

© 2024 Accesswire. All Rights Reserved.